| P2093 | author name string | Neuhaus KL | |
| | Zeymer U | |
| | Mateblowski M | |
| P2860 | cites work | Comparison of hirudin and heparin as adjuncts to streptokinase thrombolysis in a canine model of coronary thrombosis | Q70669330 |
| | Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial | Q71493537 |
| | Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris | Q71683207 |
| | Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety | Q71732646 |
| | Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial | Q71785107 |
| | Recombinant hirudin (HBW 023) produces stable anticoagulation unaffected by circadian variation in patients with thrombolysis for acute myocardial infarction | Q71875422 |
| | Thrombin generation during infusion of tissue-type plasminogen activator | Q72215676 |
| | A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial | Q72332452 |
| | Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction | Q72352876 |
| | Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase | Q72726606 |
| | Persistent thrombin generation in humans during specific thrombin inhibition with hirudin | Q72893501 |
| | Hirudin: Its Biology and Clinical Use | Q73286001 |
| | Determination of r DNA hirudin and A-human thrombin- hirudin complex in plasma samples: enzyme linked immunosorbent assays for hirudin and complex vs. chromogenic thrombin substrate assay | Q33191811 |
| | Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Relevance for the success of therapy | Q33383834 |
| | Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury | Q34576143 |
| | The pathogenesis of coronary artery disease and the acute coronary syndromes (1). | Q36728740 |
| | Development of hirudin as an antithrombotic agent | Q38735170 |
| | Coronary Plaque Disruption | Q40459835 |
| | Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase. Correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. The European Cooperative Study Group | Q41112658 |
| | Effect of thrombin inhibition on the dynamics of thrombolysis and on platelet function during thrombolytic therapy | Q44519440 |
| | A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes | Q56945341 |
| | Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction | Q57798992 |
| | Increased thrombin activity during thrombolysis | Q67963629 |
| | Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion | Q67984272 |
| | Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay | Q68337253 |
| | Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense fibrinolysis | Q69224498 |
| P433 | issue | 3 | |
| P921 | main subject | hirudin | Q386715 |
| | acute myocardial infarction | Q18558122 |
| P304 | page(s) | 203-207 | |
| P577 | publication date | 1998-07-01 | |
| P1433 | published in | Journal of Thrombosis and Thrombolysis | Q15766541 |
| P1476 | title | Thrombin Generation in Patients with Acute Myocardial Infarction Treated with Front-Loaded rt-PA and Recombinant Hirudin (HBW 023) | |
| P478 | volume | 5 | |